Loomba R, Neutel J, Mohseni R et al (2019) LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
once-weekly semaglutide 2.4 mg in adults with overweight or obesity (~15% mean weight loss)
MOTS-c covers the metabolic and exercise-mimetic angle
This peptide recovery patch is designed to complement active lifestyles and post-workout wellness routines
Am J Physiol 276(5):R1541R1544 Henness S, Keam SJ (2006) Vildagliptin Drugs 66:19892001 Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
We provide transparent pricing at consultation